Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionBispecific mAb against interleukin-4 (IL-4; BSF1) and IL-13
Molecular Target Interleukin-4 (IL-4) (BSF1) ; Interleukin-13 (IL-13)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation U.S. - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today